PERL Continuous Glucose Monitoring (CGM) Study
Public ClinicalTrials.gov record NCT03334318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Seven-point capillary profiles have shown that mean glucose correlates with both diabetic retinopathy and nephropathy risk. However, there remains great controversy as to whether the degree of variability around mean glucose may also contribute to these microvascular complications. The PERL trial (NCT02017171), testing whether treatment with allopurinol can slow down kidney function loss in type 1 diabetes, provides a unique opportunity to assess the role of glycemic variability in the progression of diabetic kidney disease in individuals who already have mild to moderate kidney disease. By applying Continuous Glucose Monitoring (CGM) in the PERL Study population, the investigators will be able to better understand how metrics of glycemia (mean, time above and below range, and various measures of variability) are associated with renal outcomes in the PERL population as a whole, but also in important subgroups (e.g., albuminuric vs. normoalbuminuric subjects with ongoing GFR decline, allopurinol vs. placebo arms). The nvestigators also aim to obtain precise information on the range of blood glucose corresponding to any given HbA1c value in this population since previous studies generally excluded patients with renal disease.
Study identification
- NCT ID
- NCT03334318
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 175 participants
Conditions and interventions
Conditions
Interventions
- Mean blood glucose Other
- Blood glucose CV Other
- % time 70-180 mg/dL Other
- % time below 54 mg/dL Other
- % time above 180 mg/dL Other
- % time above 250 mg/dL Other
- MAGE (Mean amplitude of glucose excursions) Other
- LBGI (Low Blood Glucose Index) Other
- HBGI (High Blood Glucose Index) Other
- Allopurinol Drug
- Placebo Drug
Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2017
- Primary completion
- Aug 30, 2019
- Completion
- Dec 30, 2021
- Last update posted
- Mar 28, 2022
2017 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Barbara Davis Center / University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Emory University - Grady Memorial Hospital | Atlanta | Georgia | 30303 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Joslin Diabetes Center | Boston | Massachusetts | 02215 | — |
| Brehm Center for Diabetes Research / University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| ICAHN School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Albert Einstein College of Medicine / Montefiore Medical Center | The Bronx | New York | 10461 | — |
| UT Southwestern Dallas | Dallas | Texas | 75390 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| University of Washington | Seattle | Washington | 98105 | — |
| Providence Sacred Heart Medical Center | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03334318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2022 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03334318 live on ClinicalTrials.gov.